Title |
IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights
|
---|---|
Published in |
Molecular Cancer, January 2017
|
DOI | 10.1186/s12943-016-0576-5 |
Pubmed ID | |
Authors |
Heming Li, Izhar Singh Batth, Xiujuan Qu, Ling Xu, Na Song, Ruoyu Wang, Yunpeng Liu |
Abstract |
The insulin-like growth factor-I (IGF-I) signaling induces epithelial to mesenchymal transition (EMT) program and contributes to metastasis and drug resistance in several subtypes of tumors. In preclinical studies, targeting of the insulin-like growth factor-I receptor (IGF-IR) showed promising anti-tumor effects. Unfortunately, high expectations for anti-IGF-IR therapy encountered challenge and disappointment in numerous clinical trials. This review summarizes the regulation of EMT by IGF-I/IGF-IR signaling pathway and drug resistance mechanisms of targeting IGF-IR therapy. Most importantly, we address several factors in the regulation of IGF-I/IGF-IR-associated EMT progression that may be potential predictive biomarkers in targeted therapy. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 81 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 16 | 20% |
Student > Master | 10 | 12% |
Researcher | 8 | 10% |
Student > Doctoral Student | 6 | 7% |
Professor | 4 | 5% |
Other | 9 | 11% |
Unknown | 28 | 35% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 23 | 28% |
Agricultural and Biological Sciences | 8 | 10% |
Medicine and Dentistry | 6 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
Immunology and Microbiology | 3 | 4% |
Other | 4 | 5% |
Unknown | 33 | 41% |